Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/194216
Title: | Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution |
Author: | Jiménez, Raquel Rosiñol, Laura Cibeira, María Teresa Fernández de Larrea Rodríguez, Carlos José Tovar, Natalia Rodríguez-Lobato, Luis Gerardo Bladé, Esther Moreno, David F. Oliver Caldés, Aina Bladé, J. (Joan) |
Keywords: | Mieloma múltiple Diagnòstic de plasma Cèl·lules canceroses Estudi de casos Multiple myeloma Plasma diagnostics Cancer cells Case studies |
Issue Date: | 16-Sep-2022 |
Publisher: | Springer Nature |
Abstract: | From January 1970 to December 2018, 1304 patients were diagnosed with multiple myeloma (MM) at our institution and 256 (19.6%) had plasmacytomas (Ps) (paraskeletal -PPs- 17.6%, extramedullary -EMPs-1.9%). Patients with Ps had lower serum M-protein and less advanced ISS stage than those without. At first relapse, 192 out of 967 patients (19.8%) developed Ps (PPs 14.6%, EMPs 5.1%). The only factor associated with Ps at relapse was the presence of Ps at diagnosis (46% vs 13%, p < 0.00001) with no impact with exposure to novel drugs or previous autologous stem-cell transplantation (ASCT). The median overall survival (OS) was 45, 44 and 20 months for patients without Ps, PPs and EMPs, respectively (p = 0.013). Patients with PPs who underwent ASCT had similar OS than those without Ps (98 vs. 113 months) and significantly longer than those with EMPs (98 vs 47 months, p = 0.006). In patients non-eligible for ASCT the presence of PPs or EMPs was associated with shorter OS compared with patients without Ps (32 vs. 24 vs. 6 months, p = 0.009). In the relapsed setting, a significant survival benefit was observed beyond the year 2000, but still with significant differences among patients without Ps, PPs and EMPs (37 vs 22 vs 16 months, p = 0.003). Importantly, rescue therapy with combinations of proteasome-inhibitors plus immunomodulatory drugs was associated with prolonged OS from first relapse (over 6 years), even in patients with EMPs. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41408-022-00730-5 |
It is part of: | Blood Cancer Journal, 2022, vol. 12, num. 9 |
URI: | http://hdl.handle.net/2445/194216 |
Related resource: | https://doi.org/10.1038/s41408-022-00730-5 |
ISSN: | 2044-5385 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
730848.pdf | 1.07 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License